Analysis of traditional Chinese medicine from patent information sharing platform of coronavirus disease 2019 (COVID-19).
10.19540/j.cnki.cjcmm.20200330.501
- Author:
Ke-Lu YANG
1
;
Ya GAO
2
;
Feng-Wen YANG
3
;
Ming LIU
2
;
Shu-Zhen SHI
2
;
Ya-Min CHEN
1
;
Jun-Hua ZHANG
3
;
Jin-Hui TIAN
4
Author Information
1. Evidence-based Nursing Center, School of Nursing, Lanzhou University Lanzhou 730000, China.
2. Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University Lanzhou 730000, China.
3. Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 300193, China.
4. Evidence-based Nursing Center, School of Nursing, Lanzhou University Lanzhou 730000, China Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University Lanzhou 730000, China.
- Publication Type:Journal Article
- Keywords:
2019-nCoV;
COVID-19;
patent;
traditional Chinese medicine
- MeSH:
Beijing;
Betacoronavirus;
Coronavirus Infections;
drug therapy;
Drugs, Chinese Herbal;
Humans;
Information Dissemination;
Medicine, Chinese Traditional;
Pandemics;
Pneumonia, Viral;
drug therapy
- From:
China Journal of Chinese Materia Medica
2020;45(13):3001-3006
- CountryChina
- Language:Chinese
-
Abstract:
Coronavirus disease 2019(COVID-19) is a newly emerged and highly contagious respiratory disease. Traditional Chinese medicine(TCM) has both systematism theory knowledge and clinical practical value in the prevention and treatment of COVID-19. Therefore, it was particularly important to examine the effect of TCM in the prevention and treatment of COVID-19. The patents of TCM might reflect the latest progression of scientific research. We aimed to provide reference for the prevention and treatment of COVID-19 by extracting and analyzing the TCM patents from the Patent Information Sharing Platform of COVID-19. The antiviral TCM patents were screened and exported from the Patent Information Sharing Platform. VOSviewer 1.6.14 was used to visualize and analyze the network of TCM in these patents. There were total 292 TCM patents, including 52 patents for etiological treatment and 240 patents for symptomatic treatment. Thirty-two provinces and 1 076 inventors were involved, mainly from Beijing, Guangdong and Jiangsu. Overall, there were 356 TCMs, 71 single prescriptions, and 221 compound prescriptions. The patents for treatment of coronavirus mainly focused on the treatment of coronavirus, while the patents for symptomatic treatment mainly focuses on the improvement of respiratory symptoms, such as fever and cough. There were 14 highly frequently used TCMs, including Glycyrrhizae Radix et Rhizoma, Scutellariae Radix, Lonicerae Japonicae Flos, Forsythiae Fructus, Isatidis Radix, Astragali Radix, Menthae Haplocalycis Herba, Gypsum Fibrosum, Houttuyniae Herba, Isatidis Folium, Rhei Radix et Rhizoma, Gardeniae Fructus, Platycodonis Radix, Armeniacae Semen Amarum. The analyzed results of the TCM patents from the patent information sharing platform of COVID-19 were consistent with the Guideline of Diagnosis and Treatment of COVID-19(7th edition), and the combination of TCM in each cluster may also provide future directions for drug compatibility.
